Xconomy: Genzyme Targets Growth, Taligen Takes $26M, Icahn Lays Into Biogen Idec Management, & More Boston-Area Life Sciences News
Summary
Genzyme Targets Growth, Taligen Takes $26M, Icahn Lays Into Biogen Idec Management, & More Boston-Area Life Sciences News Xconomy Boston — A good number of New England life sciences firms took home new venture money this past week—in a couple of cases, in fairly large bags.—Luke gave an overview of how Cambridge, MA-based biotech powerhouse Genzyme (NASDAQ: GENZ) plans to keep its revenues growing and its pipeline moving.Operating in incubator space at the Boston University Photonics Center, and backed by Flybridge Capital Partners and North Bridge Venture Partners, the company is developing an inexpensive, disposable “patch pump” for delivering drugs.—Luke gave an overview of the scathing new attack that billionaire investor Carl Icahn is making on the management of Cambridge, MA-based Biogen Idec (NASDAQ: BIIB).Taligen is developing drugs for inflammatory diseases that work by manipulating a part of the immune system called the “alternative complement pathway.”